Group purchasing organizations and purchasing groups, affiliations, and coalitions
We realize that in healthcare, you can’t go it alone. It takes partners and associates coming together in collaboration to achieve efficient, cost-effective care for patients. We also understand the financial and operational pressures faced by today’s hospitals and healthcare systems, because we are a hospital too. Group purchasing organizations (GPOs) and purchasing groups (PGs) help hospitals by shouldering the burden of negotiating the best member pricing and benefits with quality suppliers. At Mayo Clinic Laboratories, we welcome the opportunity to serve members by establishing relationships with their GPOs and PGs to provide member access to our broad esoteric testing menu and services.
Building laboratory value
The financial pressure on hospitals continues. To help, we can support hospital laboratories by evaluating current utilization, capacity, and processes to help reduce waste, find efficiencies, and maximize capabilities for optimal financial performance.
We also offer support in building and expanding laboratory outreach programs. Our experienced, industry-leading outreach consultants offer unparalleled insights and experience to help hospital-based laboratories evolve from cost-centers to revenue generators. Learn more about how we can support laboratories’ optimization and revenue-generation goals.
Driving efficiency through consolidation
Most hospital laboratories find themselves sending tests to an increasing number of commercial and specialty reference laboratories. Managing the complexities of these various relationships increases operational burden, staff workload, and inconsistencies in testing methods and interpretation of results.
Hospitals and health systems can optimize their laboratory testing referrals by leveraging our extensive test menu, which includes advanced diagnostics, cutting-edge technology, and clinically relevant new tests across our full spectrum of medical subspecialties.
“The type of service we provide is really tailored to the needs of the hospital or to the healthcare system. And their patients are no different than the patients that walk through our doors.”
William Morice, M.D., Ph.D., CEO and President of Mayo Clinic Laboratories
Sharing knowledge and empowering staff
We support care teams by providing insights and education as they strive to solve the most complex medical challenges. Our education offerings range from conferences to on-demand programs to webinars — many of which offer CME credit. View our extensive educational offerings.
In addition, hospital and laboratory staff have direct access to Mayo Clinic physicians and scientists, who can help with optimizing test orders and interpreting results. Mayo Clinic Laboratories provides each client with a dedicated team of account, clinical, and laboratory technical professionals.
Prioritizing patient care
With guidance from our practicing physicians, we continuously develop testing algorithms, invest in research, and develop new tests so that patients have access to the best testing available. As a hospital-based reference laboratory, our focus is helping clients prevent overutilization of laboratory testing, drive efficiency through consolidation of send-out testing, and generate hospital revenue by establishing and growing lab outreach programs. And, we provide benefits only available through a connection with a world-class medical institution: access to our Mayo Clinic physicians and consultants, educational offerings, and the most cutting-edge, clinically-based testing available in the market.
News and updates
The latest
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, to explore recent examples of diagnostic innovations that are improving patient care. Dr. Pritt also welcomes Matthew Schultz, Ph.D., a clinical biomedical geneticist at Mayo Clinic, to discuss how a novel test is delivering answers for patients with a recently identified peripheral neuropathy.
In this episode of Mayo Clinic Laboratories’ “Leveraging the Laboratory” podcast, host Jane Hermansen, outreach manager at Mayo Clinic Laboratories, speaks with outreach solutions strategists Ellen Dijkman Dulkes and Brianne Newton. They discuss how to proactively manage the variety of patient requests and interactions that occur in an outreach laboratory beyond the phlebotomy environment.
Mayo Clinic Laboratories’ BioPharma Diagnostics team supports companies from discovery to post-market in advancing their precision medicine initiatives. In this collaboration example, learn how BioPharma Diagnostics helped a biotech company complete a surveillance biomarker study to establish a cutoff for its assay developed to monitor the progression or regression of disease in patients with well-defined gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by Matthew Binnicker, Ph.D., professor of laboratory medicine and pathology and clinical virologist at Mayo Clinic. They discuss the widespread outbreaks of H5N1 bird flu and the new “FLiRT” variants of COVID-19.
William Morice II, M.D., Ph.D., president and chief executive officer of Mayo Clinic Laboratories, authored a Becker’s Healthcare article on how hospital laboratories can navigate times of change and uncertainty with the steadfast support of a business partner like Mayo Clinic Laboratories.
This week's research roundup feature: Monoclonal immunoglobulin (MIg) crystalline nephropathies are rare lesions resulting from precipitation of MIgs in the kidney as crystalline inclusions. They can be categorized into lesions with predominant intracellular crystals (light chain [LC] proximal tubulopathy, LC crystal-storing histiocytosis, LC crystalline podocytopathy] and lesions with predominant extracellular crystals (crystalglobulin-induced nephropathy, crystalline variant of LC cast nephropathy).
Robert Jenkins, M.D., Ph.D., Stephanie Smoley, CG(ASCP), and Beth Pitel, M.S., explain how Mayo Clinic Laboratories' enhanced MayoComplete Solid Tumor Panel better profiles tumor genetics. Defining tumor pathogenesis can guide targeted cancer therapy.
When patients are tasked with collecting specimens at home, the procedure can require special timing, collection steps, or storage conditions. If these aren’t clearly communicated to the patient beforehand, it can lead to confusion and unnecessary frustration. A laboratory can set up its patients for success by managing expectations when home collections are necessary. These steps can help ensure a successful experience for both patients and laboratory staff.
In this episode of “Lab Medicine Rounds,” host Justin Kreuter, M.D., interviews Douglas McMahon, M.D., from the Allergy and Asthma Center of Minnesota, to discuss how the lab supports asthma and allergy medical practice.
Rapidly progressive dementia (RPD) is an umbrella term covering many devasting conditions, including Creutzfeldt-Jakob disease (CJD). Gregory (Gregg) Day, M.D., explains how Mayo Clinic Laboratories' unique RPD evaluation and new CJD test help pinpoint diagnosis, to guide prognosis and treatment decisions.
This week's research roundup feature: Despite advances in understanding the genetic abnormalities in myeloproliferative neoplasms (MPNs) and the development of JAK2 inhibitors, there is an urgent need to devise new treatment strategies, particularly for triple negative myelofibrosis (MF) patients who lack mutations in the JAK2 kinase pathway and have very poor clinical outcomes.
Mayo Clinic Laboratories specimen pickup and delivery schedules will be altered due to the upcoming Memorial Day holiday on Monday, May 27, 2024. To ensure specimen stability and prevent delays, follow the guidelines below outlined for domestic clients and international clients.
An ideal testing partner will offer extensive expertise in assay development and analytical validation services, along with access to biospecimens. In this collaboration example, learn how Mayo Clinic Laboratories’ BioPharma Diagnostics team helped a musculoskeletal diagnostics company complete a prospective study to demonstrate its test’s performance in detecting periprosthetic joint infection (PJI) in synovial fluid.